Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 26;20(2):589-594.
doi: 10.31557/APJCP.2019.20.2.589.

Subtypes of Breast Cancer in Lao P.D.R.: A Study in a Limited-Resource Setting

Thitsamay Luangxay  1   2 , Siriphone Virachith, Kiyomi Hando, Soulideth Vilayvong, Phaengvilay Xaysomphet, Phetsamone Arounlangsy, Keokedthong Phongsavan, Makiko Naka Mieno, Naoko Honma, Masanobu Kitagawa, Motoji Sawabe
Affiliations

Subtypes of Breast Cancer in Lao P.D.R.: A Study in a Limited-Resource Setting

Thitsamay Luangxay et al. Asian Pac J Cancer Prev. .

Abstract

Aim: The purpose of this study is to evaluate the prevalence of the immunohistochemical subtypes of breast cancer among Lao women by using immunohistochemistry (according to the St. Gallen 2017 guidelines) and to study their correlation to clinicopathological features in order to help guide better treatment plans for patients. Materials and methods: Formalin-fixed and paraffin embedded tissue blocks of 76 cases of primary invasive breast cancer were retrieved from the University of Health Sciences, Vientiane, Lao PDR, from 2013 to 2016. Patients’ information and previous histological reports were reviewed. Immunohistochemistry was done using antibodies against estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2/neu) and Ki-67 (MIB-1). Results: The mean age of the patients was 49 years, and the major histologic type was invasive ductal carcinoma, NOS (90.7%). The proportion of each subtype was hormone receptor-positive and HER2-negative, 44.7%; hormone receptor-positive and HER2-positive, 3.9%; hormone receptor-negative and HER2-positive, 13.2%; and triple-negative, 38.2%. ER was positive in 40.8% of the cases, while PR was positive in 47.4%. More than half of the cases were poorly differentiated cancer (65.8%), followed by moderately differentiated (34.2%). Tumors presented with pT2 (60.5%), followed by pT3 (25.0%) and pT4 (7.9%). Conclusion: Breast cancer among Lao women is characterized by a large percentage of the triple-negative subtype that is less susceptible to hormonal treatments. The empirical treatment with tamoxifen should be reconsidered since it would be less effective to these patients. More importantly, basic pathology services should be the first requirement in Lao PDR in order to provide adequate care.

Keywords: Breast cancer; low-resources countries; immunohistochemistry; histological type; estrogen receptor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1
Figure 1
Histological and Immunohistochemical Results of Invasive Ductal Carcinoma of the Breast. A, Histological picture of the cancer; B, Human epidermal growth factor receptor 2 (Her 2) immunostaining. The cellular membrane of cancer cells are strongly positive (3+); C, Estrogen receptor (ER) immunostaining. The nuclei of cancer cells are positive; D, Progesterone receptor (PR) immunostaining. The nuclei of cancer cells are positive
See this image and copyright information in PMC

References

    1. Adebamowo CA, Famooto A, Ogundiran TO, et al. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat. 2008;110:183–8. - PubMed
    1. Andre F, Arnedos M, Goubar A, et al. Ki67-no evidence for its use in node-positive breast cancer. Nat Rev Clin Oncol. 2015;12:296–301. - PubMed
    1. Bird PA, Hill AG, Houssami N. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol. 2008;15:1983–8. - PubMed
    1. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11:359–77. - PMC - PubMed
    1. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7:e1000279. - PMC - PubMed

MeSH terms